Form 4: Neumora Therapeutics Executive Daljit Singh Aurora Reports Stock Option Repricing and Acquisition

Daljit Singh Aurora, Chief Operating and Development Officer of Neumora Therapeutics, reports the repricing of stock options and acquisition of new options at a lower exercise price, according to a Form 4 filing.

Summary

• Daljit Singh Aurora, Chief Operating and Development Officer of Neumora Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the repricing of several stock option grants to an exercise price of $1.69 per share, contingent upon stockholder approval.
• Aurora acquired 1,000,000 new stock options with an exercise price of $1.69, vesting over four years from February 13, 2025.
• Existing stock options with higher exercise prices ($4.24, $6.51, $6.36, and $18.07) were repriced to $1.69.
• The repricing is conditional on Aurora remaining in service to the Issuer through August 13, 2026.
• The filing also indicates the acquisition of additional options at the new price of $1.69 to replace the old options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the repricing could be seen as positive for incentivizing management, it also depends on stockholder approval and continued service. It's a fairly standard corporate action.

Positives

• The repricing of stock options could incentivize key personnel like Daljit Singh Aurora.
• The vesting schedule of the new options aligns with a long-term commitment to the company.

Negatives

• The repricing is contingent on stockholder approval, which introduces uncertainty.
• The repricing is also contingent on Aurora remaining in service to the Issuer through August 13, 2026.

Risks

• Failure to obtain stockholder approval for the repricing would void the changes.
• Aurora's departure before August 13, 2026, would impact the repricing terms.

Future Outlook

The repricing is subject to stockholder approval and the reporting person remaining in service to the Issuer through August 13, 2026.

Industry Context

Stock option repricing is a common practice to incentivize employees, especially when a company's stock price has declined. This move aims to retain and motivate key executives like Daljit Singh Aurora.

Comparison to Industry Standards

• Comparing Neumora's executive compensation practices to similar biotech companies like Sage Therapeutics or Biogen, stock options are a standard component of compensation packages.
• Repricing of options is not uncommon in the biotech industry, particularly after periods of stock price volatility, as seen with companies like CRISPR Therapeutics who have adjusted option plans to maintain employee motivation.
• The vesting schedules and performance-based conditions attached to these options are also in line with industry norms, ensuring alignment with long-term company performance, similar to practices at companies like Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the exercise of these options.
• Employees may be positively impacted by the increased alignment of management's interests with company performance.

Next Steps

• Obtain stockholder approval for the option repricing.
• Monitor Aurora's continued service with the company through August 13, 2026.

Key Dates